Pharmacology
News
Checkpoint inhibitor combos show promise in advanced RCC
Authors of a systematic review suggest the combinations should be widely available as first-line treatment.
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
News
Paxlovid reduces risk of COVID death by 79% in older adults
“Treatment with Paxlovid significantly reduces the risk of hospitalization and death from COVID-19.”
Conference Coverage
Sacubitril/valsartan shows cognitive safety in heart failure: PERSPECTIVE
Patients with heart failure on sacubitril/valsartan had no signal of cognitive decline, compared with controls in PERSPECTIVE, a prospective,...
News
High-dose loop diuretic can raise post–cardiac surgery mortality
Furosemide at high doses after cardiac surgeries like valve replacement or coronary bypass can prolong ICU stays and worsen mortality, a cohort...
Conference Coverage
Secondary CV prevention benefit from polypill promises global health benefit
In older patients with a prior myocardial infarction, a three-drug polypill significantly reduced risk of CV events in the multinational SECURE...
Conference Coverage
NSAIDs linked to heart failure risk in diabetes
A Danish case-crossover study found that NSAID use increased heart failure risks 50% in patients with diabetes.
News
Psychedelic drug therapy a potential ‘breakthrough’ for alcohol dependence
The effects observed with psilocybin were “considerably larger” than those of currently approved treatments for alcohol use disorder.
News
Metformin fails as early COVID-19 treatment but shows potential
Metformin may merit further investigation for adults who are overweight or obese.
News
Erlotinib promising for cancer prevention in familial adenomatous polyposis
After 6 months of weekly erlotinib, duodenal polyp burden was significantly reduced, with a mean percent reduction of 29.6%.